Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease

ORLANDO, Fla., March 26, 2018 (GLOBE NEWSWIRE) via OTC PR WIRE Immune Therapeutics, Inc. (OTCQB:IMUN) ( Immune IMUN or the Company ), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 Lodonal™ and IRT-101 MENK ) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs, today announces that it has received minutes from the Type C meeting held on January 16, 2018, between Immune Therapeutics on behalf of Cytocom, the license holder, and the US Food The post Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease appeared first on Public Wire.
http://bit.ly/2DW9UdS